asciminib

Ukraine

Drugs containing this active substance

  • SEMBLIX

    The drug is intended for the treatment of adult patients with chronic myeloid leukemia (Ph+ CML CP) in the chronic phase who have previously received two or more other tyrosine kinase inhibitors.

    Form: tablets, film-coated

    Active substance Dosage
    asciminib 20 mg

    ATC: L01EA06

    Manufacturer: Novartis Pharma Stein AG

  • SEMBLIX

    The drug is intended for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase, if they have previously received two or more other tyrosine kinase inhibitors.

    Form: tablets, film-coated

    Active substance Dosage
    asciminib 40 mg

    ATC: L01EA06

    Manufacturer: Novartis Pharma Stein AG